title: Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis.
abstract: c-Myc, a protooncogene, mediates both proliferative and cellular growth in many cell types. Although not expressed in the adult heart under normal physiological conditions, Myc expression is rapidly upregulated in response to hypertrophic stimuli. Although Myc is capable of sustaining hyperplastic growth in fetal myocytes, the effects of its re-expression in adult postmitotic myocardium and its role in mediating cardiac hypertrophy are unknown. To determine the effects of de novo Myc activity in adult postmitotic myocardium in vivo, we created a novel transgenic model in which Myc is expressed and inducibly activated specifically in cardiac myocytes. Activation of Myc in adult myocardium was sufficient to reproduce the characteristic changes in myocyte size, protein synthesis, and cardiac-specific gene expression seen in cardiac hypertrophy. Despite the increased cardiac mass, left ventricular function remained normal. Activation of Myc also provoked cell cycle reentry in postmitotic myocytes, which led to increased nuclei per myocyte and DNA content per nuclei.
authors.affiliation: Cardiovascular Research Laboratories, Department of Medicine, University of California at Los Angeles School of Medicine, Friederich-Wilhelms University of Bonn, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Xiao
authors.forename: S
authors.initials: S
authors.lastname: Mao
authors.forename: G
authors.initials: G
authors.lastname: Baumgarten
authors.forename: J
authors.initials: J
authors.lastname: Serrano
authors.forename: M C
authors.initials: MC
authors.lastname: Jordan
authors.forename: K P
authors.initials: KP
authors.lastname: Roos
authors.forename: M C
authors.initials: MC
authors.lastname: Fishbein
authors.forename: W R
authors.initials: WR
authors.lastname: MacLellan
mesh_terms: D000818:Animals; D006332:Cardiomegaly / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis*; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D008024:Ligands; D051379:Mice; D008809:Mice, Inbred C3H; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D018995:Myosin Heavy Chains / Q000235:genetics; D009929:Organ Size / Q000187:drug effects; D009928:Organ Specificity / Q000187:drug effects; D011003:Ploidies; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects; D024723:Ventricular Myosins / Q000235:genetics
chemical_list: D008024:Ligands; D016271:Proto-Oncogene Proteins c-myc; D011960:Receptors, Estrogen; D011993:Recombinant Fusion Proteins; D013629:Tamoxifen; C016601:afimoxifene; D004247:DNA; D024723:Ventricular Myosins; D018995:Myosin Heavy Chains